Skip to main content

Gallagher Cam's Form 4 filing

Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Nov 8, 2022

Accession no.
0001725160-22-000194
Filed
Nov 8, 2022
Trade date
Nov 7-8, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $587.4K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gallagher CamCIK 0001557832Director, Officer (President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 7, 2022Common StockSSaleDisposed−12,343$23.66F2−$292,035.38397,042Direct
Nov 7, 2022Common StockSSaleDisposed−157$24.24F3−$3,805.68396,885Direct
Nov 8, 2022Common StockSSaleDisposed−12,374$23.56F4−$291,531.44384,511Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.16 to $24.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.22 to $24.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.18 to $23.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)